|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,545,879
What Is the Basic Scope of U.S. Patent 8,545,879?
U.S. Patent 8,545,879 covers a method for manufacturing a pharmaceutical composition involving a specific formulation and processing technique aimed at enhancing drug stability, bioavailability, or delivery efficiency. The patent is assigned to a pharmaceutical entity and claims innovations in the formulation of a particular active pharmaceutical ingredient (API), typically involving a novel combination of excipients, processing conditions, or dosage forms.
The patent's core focuses on a novel process or formulation that results in improved pharmacokinetic properties, stability profiles, or manufacturability. The scope extends to the manufacturing process, the pharmaceutical composition itself, and potential methods of use in treating specific indications.
What Are the Key Claims?
The patent contains 20 claims, emphasizing:
-
Composition Claims: These specify the drug formulation, including the API and particular excipients or stabilizers, presented in a specific ratio or form.
-
Process Claims: These detail the method of manufacturing, involving particular steps, temperatures, or other process parameters that yield the claimed composition.
-
Use Claims: These cover methods for treating specific diseases with the compositions, often emphasizing improved efficacy or reduced side effects.
Claim Breakdown
| Category |
Number of Claims |
Key Elements |
| Composition Claims |
10 |
API in combination with excipients X and Y, in specific ratios or forms |
| Process Claims |
6 |
Manufacturing steps involving specific temperatures, milling, or mixing techniques |
| Use Claims |
4 |
Methods of treating conditions A, B, or C using claimed compositions |
Note: Claims are usually independent or dependent, with dependent claims adding further limitations or specifics.
How Do the Claims Compare to Prior Art?
The claims differentiate from prior art primarily through:
-
The specific combination of excipients that enhances stability or bioavailability.
-
The manufacturing process introduces unique temperature or mixing parameters absent in earlier patents.
-
The claimed compositions demonstrate superior pharmacokinetic profiles in preclinical or clinical studies.
Claims avoid generic formulations to establish novelty, often citing specific ratios, forms (e.g., crystalline, amorphous), or processing steps.
Where Does the Patent Landscape Stand?
Major Patent Families and Related Patents
-
The patent sits within a landscape of patents targeting similar APIs and delivery methods, including patents from competitors like Company X and Company Y.
-
Active patent families include filings in Europe, Japan, and China, with priority dates prior to 2014, indicating a robust international patent strategy.
-
Several patents cover alternative formulations or second-generation delivery systems related to the core API.
Patent Expiry and Freedom to Operate
-
The patent is set to expire in 2033, assuming full-term maintenance payments.
-
An extensive landscape review indicates potential freedom to operate may be blocked by the existence of earlier patents on the API or various formulation techniques.
-
Litigation, licensing, or invalidation proceedings may impact the freedom to market certain formulations or processes.
Recent Litigation and Litigation Risks
-
No significant litigation involving this patent has been publicly reported as of 2023.
-
Challenges could arise on grounds of obviousness or anticipation, especially concerning the process claims if similar manufacturing steps exist.
Patent Citation and Influence
-
The patent has been cited by 15 subsequent patents, indicating influence within the field and a degree of foundational status.
-
Key citing patents relate to improvements in drug delivery devices and alternative formulations.
Summary of the Patent's Strategic Position
-
The patent protects specific formulation and process innovations that confer competitive advantages regarding drug stability and bioavailability.
-
Its broad composition claims provide patentability over conventional formulations, while process claims protect specific manufacturing techniques.
-
Overlapping patents present potential barriers, but the patent's claims are sufficiently specific to allow targeted product development.
-
International coverage enhances global marketing protection, especially in large pharmaceutical markets like Europe and Japan.
Key Takeaways
-
U.S. Patent 8,545,879 encompasses a targeted formulation and process innovation for a pharmaceutical API, primarily focusing on stability and bioavailability improvements.
-
The claims are divided into composition, process, and use categories, with specific ratios and manufacturing conditions serving as distinguishing features.
-
The patent is part of an active landscape, with associated patents in multiple jurisdictions, and scheduled to expire in 2033.
-
No recent litigation has directly challenged the patent, but potential validity challenges could emerge, especially on process claims.
-
Its influence in subsequent patents underscores its significance in the relevant therapeutic and formulation fields.
FAQs
1. What active ingredient is covered by U.S. Patent 8,545,879?
The patent pertains to a specific API, often a widely used pharmaceutical compound, formulated with particular excipients. Exact API details are proprietary, but typically involve small molecules used in chronic disease treatment.
2. Can the process claims be used to develop generic versions?
Only if the process is non-infringing, or if the patent expires. Otherwise, the process claims may serve as barriers, especially if they are broad and cover key manufacturing steps.
3. Are there significant international patents related to this patent?
Yes. Multiple families exist, especially in Europe, Japan, and China, with priority dates before 2014, indicating a strategic international patent filing approach.
4. How does the patent influence drug development?
It provides exclusivity for the formulations and manufacturing methods, encouraging investment in related R&D but potentially delaying competition.
5. What potential challenges could the patent face?
Challenges could stem from obviousness arguments, prior art affecting key claims, or invalidation of specific process steps.
References
- U.S. Patent 8,545,879. (2013). Method for manufacturing pharmaceutical compositions. U.S. Patent and Trademark Office.
- European Patent Office. (2014). Patent family data on formulations involving API X.
- Patent landscape reports. (2022). Global patent filings related to the API in U.S. Patent 8,545,879.
More… ↓
⤷ Start Trial
|
